• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

CardioDx Inc.

CardioDx resurrects IPO dreams

April 30, 2014 By Arezu Sarvestani Leave a Comment

CardioDx resurrects IPO dreams

More than 5 months after ditching efforts to open on public markets, California-based CardioDx is ready to take another swing at an initial public offering.

In regulatory documents filed this week the molecular diagnostics maker assigned new underwriters, named a couple of new executives and added 2 members to its board of directors. CardioDx has not yet revealed exact timing or terms for the revived IPO.

Filed Under: Genomics/Molecular Diagnostics, Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: CardioDx Inc.

CardioDx spikes IPO

November 15, 2013 By Brad Perriello Leave a Comment

CardioDx spikes IPO

California molecular diagnostics company CardioDx spiked its initial public offering, citing "unfavorable market conditions," according to news reports.

The 5.8-million-share offering by Palo Alto-based CardioDx was slated to raise $92 million at a share price of $14-$16 apiece. The IPO, originally scheduled for yesterday, would have seen CardioDx shares trade under the "CDX" symbol.

Filed Under: Genomics/Molecular Diagnostics, Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: CardioDx Inc.

CardioDx aims for $92M IPO

November 6, 2013 By Arezu Sarvestani Leave a Comment

CardioDx aims for $92M IPO

California molecular diagnostics company CardioDx unveiled new details of its initial public offering, slated to raise $92 million through shares priced at $14-$16 apiece.

Once the IPO launches, CardioDx will trade on the Nasdaq stock market under the symbol "CDX."

Filed Under: Funding Roundup, Genomics/Molecular Diagnostics, Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: CardioDx Inc.

CardioDx IPO may fetch $86.3 million

October 16, 2013 By Arezu Sarvestani Leave a Comment

CardioDx IPO may fetch $86.3 million

CardioDx is planning something big, although it hasn’t released the full details of its upcoming initial public offering. The Palo Alto, Calif.-based genetic testing company filed preliminary documents for a maximum aggregate offering of up to $86.3 million.

CardioDx hasn’t yet released details of the offering, so the number of shares and individual pricing remains a mystery, but the company has laid out its plans for how it’ll spend the money it hopes to raise.

Filed Under: Funding Roundup, Genomics/Molecular Diagnostics, Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: CardioDx Inc.

Intrinsic Therapeutics puts a new man in charge | Personnel Moves

September 22, 2011 By MassDevice staff Leave a Comment

Intrinsic Therapeutics

Intrinsic Therapeutics named Wright Medical (NSQD:WMGI) veteran Cary Hagan as its new President & CEO. Greg Lambrect, founder of Intrinsic will stay on as executive director.

"Cary’s proven success in bringing new technologies to the global market makes him an ideal choice to lead Intrinsic’s next stage of growth as we expand our international clinical and commercial activity," said Lambrecht in prepared remarks.

Filed Under: News Well Tagged With: AdvaMed, CardioDx Inc., General Electric, Hanger Inc., Personnel Moves, PPD Inc., Quanterix Corp., SANUWAVE Health Inc., Securities & Exchange Commission (SEC), Vicor Corp.

Guggenhime and Monane join the CardioDx team

September 21, 2011 By MassDevice Leave a Comment

CardioDx Appoints Andrew Guggenhime as Chief Financial Officer and Mark Monane, M.D., as Chief Medical Officer

Two Key Hires Position Company for Continued Growth

PALO ALTO, Calif.–(BUSINESS WIRE)–CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced the hires of Andrew L. Guggenhime as the company’s chief financial officer and Mark Monane, M.D., as chief medical officer.

Filed Under: Uncategorized Tagged With: CardioDx Inc., Personnel Moves

Pacemakers, heart disease diagnostics and weight-loss devices draw the most VC attention in 2011 | MassDevice.com On Call

August 25, 2011 By MassDevice staff Leave a Comment

MassDevice On Call

MASSDEVICE ON CALL — Implantable defibrillators, coronary artery disease tests and implantable obesity treatment devices got the most venture capital attention in the first half of 2011, topping a list of the 10 biggest VC deals so far this year.

Coming in at number one, Cameron Health rounded up $107 million from Alloy Ventures and Delphi Ventures for its landmark completely subcutaneous  implantable defibrillator, which has yet to win FDA clearance.

Filed Under: News Well, Structural Heart, Wall Street Beat Tagged With: Cameron Health Inc., CardioDx Inc., Gastrointestinal, GE Healthcare, IntraPace Inc., Venture Capital/Private Equity

Quintiles aims to restructure debt with $2 billion in credit | Funding roundup

May 13, 2011 By MedCity News

Funding

Quintiles is resuming its plans to raise more than $2 billion in bank financing.

The Durham, N.C.-based, contract research organization is planning to enter into a new $2.2 billion credit facility, with proceeds from the borrowed funding being used to refinance $1.7 billion in existing debt, including an offer to buy $525 million of 9.5 percent outstanding senior notes that are due in 2014.

Filed Under: News Well Tagged With: Advanced BioHealing Inc., Angiotech, Avedro Inc., CardioDx Inc., Cardiva Medical Inc., DaVita Inc., Lantheus Medical Imaging, Life Technologies Corp., MindChild Medical Inc., MoMelan Technologies, Quintiles, Seventh Sense Biosystems Inc., Sorin Group, Varian Medical Systems, Venture Capital/Private Equity, WaveMark Inc., WaveTec Vision

CardioDx drums up $57 million for genetic tests | Funding roundup

March 9, 2011 By MassDevice staff Leave a Comment

Funding Roundup

CardioDx Inc. raised $57.5 million from equity and options investments, according to its latest filing with the Securities & Exchange Commission.

The Palo Alto, Calif.-based genomics firm is developing tests based on gene expression analysis to measure patients’ risk for cardiovascular diseases.

The new financing, which is part of the $78.3 million the company is trying to raise, was supported by 17 unnamed investors, according to the SEC filing.

Filed Under: Genomics/Molecular Diagnostics, News Well Tagged With: CardioDx Inc., Image Stream Medical Inc., Nephros, Rotech Healthcare Inc.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS